EL7.AI
StocksMedium•30 March 2026•
1 min read

Rocket Pharmaceuticals Shares Slide Despite FDA Nod for Kresladi Gene Therapy

Key Facts

1Rocket Pharmaceuticals received FDA accelerated approval for its gene therapy, Kresladi.
2The therapy targets severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare genetic disease.
3RCKT stock price declined following the announcement despite the positive regulatory news.

Rocket Pharmaceuticals (RCKT) shares experienced a decline despite receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for its gene therapy, Kresladi. The therapy is designed to treat severe leukocyte adhesion deficiency-I (LAD-I), a life-threatening ultra-rare genetic disorder. While the regulatory milestone is a significant achievement for the biotech firm, the market reacted negatively, with the stock price dropping following the announcement. Analysts suggest the decline may be attributed to a "sell the news" dynamic, as the approval was largely anticipated by investors. Additionally, concerns regarding the commercial scalability and long-term profitability of a treatment for such a rare condition may be weighing on investor sentiment. This development highlights the volatility often seen in the biotech sector following major regulatory decisions.